United Kingdom Regulators Approve Higher Wegovy Dosage
The MHRA has authorized a 7.2 milligram weekly dose of Wegovy for patients with obesity. This higher dose offers increased weight loss results of 20 percent.
Insights:
The Medicines and Healthcare products Regulatory Agency in the United Kingdom 
GBapproved a maximum weekly dose of 7.2 milligrams of the weight-loss drug Wegovy on January 6, 2026. This decision by regulators in the United Kingdomexpands treatment options for patients with obesity, defined as a body mass index of 30 or higher. Developed by Novo Nordisk A/S , the higher dose is administered as three separate injections and has been shown to deliver approximately 20 percent weight loss in clinical trials. This is an increase from the 15-16 percent weight loss associated with the previously approved 2.4 milligram dose.
GBapproved a maximum weekly dose of 7.2 milligrams of the weight-loss drug Wegovy on January 6, 2026. This decision by regulators in the United Kingdomexpands treatment options for patients with obesity, defined as a body mass index of 30 or higher. Developed by Novo Nordisk A/S , the higher dose is administered as three separate injections and has been shown to deliver approximately 20 percent weight loss in clinical trials. This is an increase from the 15-16 percent weight loss associated with the previously approved 2.4 milligram dose.
